The Multiple Myeloma Research Foundation
American Society for Hematology (ASH) Meeting & Exhibition 2019

The MMRF will be in Orlando for ASH 2019 at

Booth #2117

The American Society for Hematology (ASH) Meeting & Exhibition 2019

December 7 – 10: Orange County Convention Center, Orlando, FL

ASH is the most comprehensive hematology event of the year. The meeting will highlight the most exciting clinical research in hematology.

The MMRF will be presenting abstracts, daily blog updates, and daily social media posts.

View our press release

MMRF updates from ASH:

Current Obstacles in Myeloma Management: Debating the Evidence

Friday, December 6: 7:00 - 11:00 AM

Join us on Friday, December 6, 2019, for a CME-certified Friday Satellite Symposium preceding the 61st American Society of Hematology (ASH) Annual Meeting and Exposition.

Register here

ASH Daily Blog Updates

Get the latest clinical information from ASH 2019 via MMRF daily blogs from our medical professionals and partners.

MMRF Continues to Accelerate Discoveries and Breakthroughs
Read about the MMRF presentations occurring at this year's ASH meeting in our press release.

View Press Release

Day 1 - CAR T-Cells Session
We kick off this year’s American Society of Hematology (ASH) meeting covering two presentations that discuss the very hot topic of chimeric antigen receptor (CAR) T-cells.

View Post

Day 1 - New Therapies & XPOVIO Session
In the mid-morning session today, we heard about many new therapies being studied in myeloma and learned more about the newly approved drug—XPOVIO—as part of a triplet combination therapy.

View Post

Day 1 - Improving CAR T-Cell Therapy Session
The last abstract to be covered for today focuses on chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on myeloma cells.

View Post

Day 3 - Improving CAR T-Cell Therapy, LCAR-B38M and SMM Treatment Session
Learn more about CAR T-cell therapy — 3 new constructs and the long-term follow-up results from a trial of construct we’ve reported on last year — LCAR-B38M. Also presented were a couple of studies on the treatment of patients with smoldering multiple myeloma (SMM).

View Post

Day 3 - Newly Diagnosed Myeloma & Relapse Predictors Session
The second morning session today focused on newly diagnosed myeloma and various combination strategies, as well as predictors of relapse.

View Post

Day 3 - Combination Therapies for the Newly Diagnosed Session
Monday’s early evening session covered a variety of combination therapies all with the goal of improving the outcome for newly diagnosed multiple myeloma patients.

View Post

Day 3 - Venclexta & Immunotherapies Session
The last myeloma session of the day follows the same theme as the first day—with presentations on new drugs: Venclexta (venetoclax) and immunotherapies!

View Post

Day 4 - Late-Breaking Abstract Session
We close out the 2019 ASH meeting with one final presentation from the late-breaking abstract session.

View Post

Multiple Myeloma Highlights From the 2019 ASH Meeting & Exposition

Wednesday, December 18: 1:00 - 2:00 PM EST

Please join us for a FREE webinar developed to provide patients with a summary of the most exciting clinical research on multiple myeloma presented at the 61st Annual Meeting & Exposition of the American Society of Hematology.

Register here

Follow us during ASH: